INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire • 9 hours ago

What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call

ClearPoint Neuro NASDAQ: CLPT reported third-quarter 2026 revenue growth of 36% as sales increased across its biologics and drug-delivery, neurosurgery navigation and therapy, and capital equipment and software businesses. Management said the company is investing in clinical support, laboratory capabilities and product development as it prepares for anticipated cell and gene therapy trial activity and potential commercial launches.

MarketBeat • a day ago

ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript

Seeking Alpha • a day ago

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.21 per share a year ago.

Zacks Investment Research • a day ago

ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026

SOLANA BEACH, CA / ACCESS Newswire / October 14, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 third quarter on Wednesday, October 28, 2026, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 third quarter on Wednesday, October 28 at 4:30 p.m.

Accesswire • Oct 14, 2026

CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $CLPT--CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law.

Business Wire • Oct 8, 2026

Cedar Grove Capital Q3 2026 Portfolio Update

During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.

Seeking Alpha • Oct 7, 2026

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 4, 2026

ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case

ClearPoint Neuro's second quarter results were poor across the board, with drug delivery disposables an area of particular weakness. Delays in the ramping of preclinical services at ClearPoint's new facility have also contributed to reduced expectations for 2026. There is now regulatory clarity, though, meaning a revenue inflection as AMT-130 is commercialized is now highly likely in 2027/2028.

Seeking Alpha • Aug 4, 2026

ClearPoint Neuro Q2 Earnings Call Highlights

ClearPoint Neuro NASDAQ: CLPT reported second-quarter 2026 revenue growth while outlining a shift in investment priorities toward clinical capacity, preclinical laboratory services and technologies intended to support commercial-scale neuro drug delivery.

MarketBeat • Aug 3, 2026